Leerink reiterates Market Perform on Sarepta stock after siRNA data

Leerink reaffirmed a Market Perform rating and $15 price target on Sarepta (shares $22.04), while the stock is down ~76% year-over-year; analysts still forecast $4.06 EPS for 2026. Early Phase 1/2 siRNA data (SRP-1001, SRP-1003) showed dose-dependent muscle exposure and early biomarker effects but disclosures were limited to single ascending dose cohorts and omitted key splicing (Casi22) data, disappointing some investors. Sarepta plans supplemental NDAs by end-April to convert accelerated approvals for Amondys 45 and Vyondys 53 to traditional approvals; BofA reiterated Underperform while Jefferies remains Buy. Additional multiple-ascending-dose data expected in H2 2026 and firms view the siRNA program as potential upside to current estimates.

Analysis

Market pricing has already baked in elevated execution and regulatory risk for assets with complex oligonucleotide payloads, so any incremental visibility on manufacturing reproducibility or broader biomarker disclosure will de-risk the story non-linearly. Assay-validation timing slippage (a process signal, not just a calendar one) often presages either higher follow-on capital needs or tougher regulatory scrutiny; both compress near-term multiples but increase optionality value if the company clears the procedural hurdle.

A concentrated disclosure cadence creates two second-order market behaviors: (1) intraday volatility spikes around partial data releases that attract gamma-seeking flows and increase implied volatility, and (2) persistent investor skepticism that pressures liquidity, widening bid-ask spreads and making funded accumulation more expensive. This dynamic favors staged, protected exposure rather than naked directional punts and makes near-term option structures cheaper to buy for downside protection than they were 6–12 months ago.

Separately, a successful scale-up for any siRNA program would shift downstream demand to specialized CDMOs and LNP/oligo supply chains; that creates a low-beta way to capture upside via select contract manufacturers and service providers over a 12–36 month horizon. The regulatory pathway for converting accelerated to full approvals is a binary that dominates valuation until resolved, so market moves will be event-driven and amplified by sentiment; position sizing should reflect that binary asymmetry.

Key Decisions for Investors

• Event-protected accumulation (SRPT): Allocate up to 1–2% portfolio weight by buying common stock in tranches tied to incoming data cadence, while buying 6-month puts 25% OTM sized at 25% of the equity exposure to cap downside. Risk/Reward: limits drawdown to ~15–25% on the tranche while leaving upside uncapped into successful derisking (potential 2–4x on positive binary outcomes).
• Leveraged upside via call spread (SRPT): Buy a 9–12 month call spread sized as 0.5–1% portfolio risk—long 50% OTM / short 150% OTM—to express optionality on next-stage clinical readouts. Risk/Reward: defined max loss (premium) with asymmetric upside if data surprises; expected payoff skew >3x on positive catalyst while losing only premium on disappointments.
• Market-neutral event play (pair): Go long SRPT stock and short XBI to neutralize beta (size to zero market exposure) for a 6–12 month horizon around data/regulatory milestones. Risk/Reward: isolates company-specific execution/regulatory resolution (limited market noise) — expected positive idiosyncratic return if company delivers clarity; hedge reduces sector drawdowns.
• Supply-chain exposure (CTLT): Buy Catalent (CTLT) over 12–36 months as a low-beta play on growing oligo/siRNA manufacturing demand. Risk/Reward: steady revenue/cashflow capture from outsourced scale; downside limited relative to small-cap biotech outcomes but correlated upside to commercial success in this modality.